Maryland Prescription​ Drug Monitoring Program​

​PDMP Updates

PDMP Registration​

Please click on the PDMP logo button below for access to the CRISP's PDMP Registration Homepage.

PDMP logo.jpg​​ 

PDMP Use Mandate 

Effective July 1, 2018, a Prescription Drug Monitoring Program (PDMP) use mandate for providers prescribing controlled dangerous substances (CDS) medications and pharmacists goes into effect.  The full text of the use mandate can be found in Health General-Article § 21-2A-04.2. 

The requirements and exemptions of this mandate are summarized below. 

Mandatory Use for Prescribers:  Prescribers must query PDMP data (through the CRISP portal or integration within the Electronic Health Record (EHR), where available), assess the PDMP

1.      Before beginning new course of treatment with opioid or benzodiazepine

2.      If course of treatment extends beyond 90 days, then at least every 90 days before prescribing or dispensing opioid or benzodiazepine


Exceptions to this mandate, as explicitly listed in statute, include prescribers who are exempted from the above requirements if a prescription is written: 

1.      For no more than 3 days supply

2.      For cancer treatment or cancer-related pain

3.      To a patient in an inpatient hospital

4.      To a patient in hospice

5.      To a patient residing in nursing or other assisted living facility

6.      To treat or prevent acute pain for a period of not more than 14 days following:

a.       Surgery with general anesthesia

b.       Fracture

c.       Significant trauma

d.      Childbirth

7.      For a specific medicine included in a list compiled by the Secretary of drugs with low potential for abuse

8.      In the event of electrical or technological issues


Mandatory Use for Pharmacists: Pharmacists must query and assess the PDMP data when they suspect any CDS prescription is being filled for something other than treatment of an existing medical diagnosis, essentially a restatement of their corresponding responsibility under federal regulations.


Effective adoption of PDMP as a clinical decision support tool both under the use mandate, and as recommended by the Centers for Disease Control and Prevention (CDC), the President’s Commission on Combating Drug Addiction and the Opioid Crisis, and the Maryland Heroin and Opioid Emergency Task Force relies on integrating PDMP data access into the realities of a put in place to assist providers are:


1)      Use of Delegates, who can access the PDMP on behalf of a prescriber or pharmacist and provide that PDMP data report to the provider for a prescribing or dispensing decision

2)      Integrating PDMP access into an EHR, which is available in many hospital system settings across the state​


Official Reports